LOS ANGELES, CA — (Marketwire) — 01/09/13 — (OTCQB: MMRF) (“MMR”) today announced that it has received two additional patents adding 57 additional claims to the Company-s patent portfolio to expand the scope of the Company-s patent protection to include insurance, legal, accounting, mortgage and other types of important documents when combined with a (PHR). MMR is a leading provider of Personal Health Records through its PHR, storage solutions and MMRPro document management and imaging systems for . With the award of the two newest patents, the Company-s patent portfolio includes seven issued patents including U.S. Patent No. 8,352,287, U.S. Patent No. 8,352,288, and U.S. Patent Nos. 8,121,855; 8,117,646; 8,117,045; 8,301,466 and 8,321,240. The Company also has additional U.S. Applications and continuation applications on file plus numerous other issued patents and pending applications in other countries of commercial interest including Australia, Singapore, New Zealand, Mexico, Canada, Hong Kong, Japan, South Korea, Israel, and European nations.
According to John Goodhue at McKee, Voorhees & Sease (), “These most recent patents help expand the Company-s claims beyond healthcare. MMR has demonstrated the ways in which it has innovated in health information technology including methods to provide patients meaningful access to their personal health information while creating EsafeDepositBox storage solutions through Web-based portals or PHRs. As the industry approaches the 2014 requirements for Meaningful Use Stage 2 and continues towards Stage 3, the relevance of these innovations will continue to grow.”
“U.S. Patent No. 8,352,288 is also significant in that it relates to collecting records from service providers in addition to healthcare providers solidifying MMR-s position in the online medical records market while simultaneously including methods and systems for storage of other types of important documents,” continued Goodhue.
MMR is also offering licenses to more than 1,000 hospitals, group practices, and EMR and PHR providers through letters, sales presentations and other public forums. As a result, the Company has reached license agreements and/or is in the process of entering into strategic business relationships with EMR and PHR vendor(s), retailers and other wellness and healthcare providers. Additionally, MMR is working through trade associations with regard to selling and licensing the Company-s products and services and IP to thousands of organization members.
The Company-s newest patents also include methods as to how patients request medical information from hospitals and physicians as well as claims providing for permission-based systems that allow healthcare professionals or other service providers to use a Web-based service to send and store health records and other important documents by fax, email, or otherwise while applying different levels of security to records in a PHR.
MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc., provides secure and easy-to-use online Personal Health Records (“PHRs”) and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, retail pharmacies, and professional organizations and affinity groups. The PHR enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. MyMedicalRecords is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user-s account. The Company-s professional offering, , is designed to give physicians- offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time through an integrated patient portal. Through its merger with Favrille, Inc. in January 2009, the Company acquired intellectual property biotech assets that include anti-CD20 antibodies and data and samples from its FavId/Specifid vaccine clinical trials for the treatment of B-Cell Non-Hodgkin-s lymphoma. To learn more about MMRGlobal, Inc. visit . View demos and video tutorials of the Company-s products and services at .
All statements in this press release that are not strictly historical in nature, including, without limitation, intellectual property licenses, potential intellectual property enforcement actions, infringement claims or litigation, and future performance, management-s expectations, beliefs, intentions, estimates or projections, constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company-s actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words (and their derivations) such as “need,” “possibility,” “potential,” “intend,” “offer,” “development,” “if,” “negotiate,” “when,” “begun,” “believe,” “achieve,” “will,” “estimate,” “expect,” “maintain,” “plan,” and “continue,” or the negative of these words. Actual outcomes and results of operations and the timing of selected events may differ materially from the results predicted, and any reported results should not be considered as an indication of future performance. Such statements are necessarily based on assumptions and estimates and are subject to various risks and uncertainties, including those relating to the possible invalidity of the underlying assumptions and estimates and possible changes or developments in economic, business, industry, market, legal and regulatory circumstances and conditions and actions taken or omitted to be taken by third parties, including customers, suppliers, business partners, potential licensees, competitors and legislative, judicial and other governmental authorities and officials. Factors that could cause or contribute to such differences include, but are not limited to: unexpected outcomes with respect to intellectual property enforcement actions, claims of intellectual property infringement and general intellectual property litigation; our ability to maintain, develop, monetize and protect our patent portfolio for both the Company-s health IT and biotechnology intellectual property assets in the U.S. and internationally; the timing of milestone payments in connection with licensing our intellectual property; our ability to establish and maintain strategic relationships; changes in our relationships with our licensees; the risk the Company-s products are not adopted or viewed favorably by the healthcare community and consumer retail market; business prospects, results of operations or financial condition; risks related to the current uncertainty and instability in financial and lending markets, including global economic uncertainties; the timing and volume of sales and installations; the length of sales cycles and the installation process; the market-s acceptance of new product and service introductions; competitive product offerings and promotions; changes in government laws and regulations including the 2009 HITECH Act and changes in Meaningful Use and the 2010 Affordable Care Act; future changes in tax legislation and initiatives in the healthcare industry; undetected errors in our products; the possibility of interruption at our data centers; risks related to third party vendors; risks related to obtaining and integrating third-party licensed technology; risks related to a security breach by third parties; risks associated with recruitment and retention of key personnel; other litigation matters; uncertainties associated with doing business internationally across borders and territories; and additional risks discussed in the Company-s filings with the Securities and Exchange Commission. The Company is providing this information as of the date of this release and, except as required by applicable law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.
Michael Selsman
Public Communications Co.
(310) 922-7033
You must be logged in to post a comment Login